Adults 35 to 80, any sex, with Anatomic Stage I Breast Cancer AJCC v8 or Anatomic Stage II Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Dyadic Coping - Active EngagementPrimary· Baseline, 3, 6 and 12 months
Measured by the Active Engagement subscale from the Relationship Focused Coping Scale. The subscale assesses the degree with which couples practice active engagement by responding to five items on a Likert scale from 1 (never) to 5 (very often). Scores range from 5 to 25, with higher scores indicating more active engagement. Reported values reflect the estimated slope over 6-months.
Measured by the Protective Buffering Subscale from the Relationship Focused Coping Scale. Assesses the degree with which couples practice protective buffering by responding to six items using a Likert scale of 1 (never) to 5 (very often). Scores range from 6 to 30 with higher scores indicating more protective buffering. Reported values reflect the estimated slope over 6-months.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.48
-1.24 – 0.29
Arm II (Supervised Exercise Separately)
-0.18
-0.93 – 0.57
Arm III (Unsupervised Exercise Separately)
-0.13
-0.93 – 0.66
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.21
-0.91 – 0.50
Arm II (Supervised Exercise Separately)
-0.46
-1.16 – 0.24
Arm III (Unsupervised Exercise Separately)
-0.57
-1.34 – 0.20
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.36
-0.39 – 1.10
Arm II (Supervised Exercise Separately)
-0.09
-0.81 – 0.62
Arm III (Unsupervised Exercise Separately)
0.36
-0.44 – 1.15
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.04
-0.75 – 0.68
Arm II (Supervised Exercise Separately)
-0.20
-0.91 – 0.51
Arm III (Unsupervised Exercise Separately)
-0.27
-1.07 – 0.54
Emotional IntimacyPrimary· Baseline, 3, 6 and 12 months
Measured by the 7-item Dyadic Adjustment Scale (DAS) to assess each partner's satisfaction with their relationship by answering 7 questions on a 6-point scale ranging from 1(always agree) to 6 (always disagree). Scores range from 0-21 with higher scores indicating better dyadic adjustment. Reported values reflect the estimated slope over 6-months.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
3.37
.78 – 5.97
Arm II (Supervised Exercise Separately)
2.61
.06 – 5.15
Arm III (Unsupervised Exercise Separately)
2.97
.20 – 5.73
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-2.87
-5.84 – .10
Arm II (Supervised Exercise Separately)
-2.30
-5.26 – .67
Arm III (Unsupervised Exercise Separately)
-1.33
-4.66 – 2.01
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
.98
-1.25 – 3.20
Arm II (Supervised Exercise Separately)
1.90
-.24 – 4.05
Arm III (Unsupervised Exercise Separately)
-.99
-3.42 – 1.43
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-2.63
-5.01 – -.26
Arm II (Supervised Exercise Separately)
-.43
-2.73 – 1.88
Arm III (Unsupervised Exercise Separately)
1.96
-.64 – 4.56
Physical Intimacy - Engagement in SexPrimary· Baseline, 3, 6 and 12 months
Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in sexual behaviors answering two questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 2 to 8 with higher scores indicating higher physical intimacy.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.08
-0.23 – 0.40
Arm II (Supervised Exercise Separately)
-0.04
-0.34 – 0.26
Arm III (Unsupervised Exercise Separately)
-0.07
-0.42 – 0.29
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.02
-0.29 – 0.24
Arm II (Supervised Exercise Separately)
0.19
-0.07 – 0.44
Arm III (Unsupervised Exercise Separately)
-0.02
-0.32 – 0.28
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.10
-0.20 – 0.39
Arm II (Supervised Exercise Separately)
0.16
-0.11 – 0.43
Arm III (Unsupervised Exercise Separately)
-0.08
-0.41 – 0.24
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.12
-0.41 – 0.17
Arm II (Supervised Exercise Separately)
-0.23
-0.50 – 0.05
Arm III (Unsupervised Exercise Separately)
0.03
-0.30 – 0.35
Physical Intimacy - Engagement in Affectionate BehaviorsPrimary· Baseline, 3, 6, and 12-months
Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in affectionate behaviors answering four questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 4 to 16 with higher scores indicating higher physical intimacy.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.37
-0.18 – 0.92
Arm II (Supervised Exercise Separately)
0.08
-0.45 – 0.60
Arm III (Unsupervised Exercise Separately)
0.19
-0.41 – 0.79
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.04
-0.57 – 0.49
Arm II (Supervised Exercise Separately)
0.02
-0.50 – 0.54
Arm III (Unsupervised Exercise Separately)
0.15
-0.45 – 0.74
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.30
-0.22 – 0.82
Arm II (Supervised Exercise Separately)
0.29
-0.22 – 0.79
Arm III (Unsupervised Exercise Separately)
0.23
-0.36 – 0.82
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.37
-0.93 – 0.18
Arm II (Supervised Exercise Separately)
-0.18
-0.72 – 0.36
Arm III (Unsupervised Exercise Separately)
-0.15
-0.79 – 0.50
Concealment of SymptomsPrimary· Baseline, 3, 6 and 12 months
Measured by the Emotional-Intimacy Disruptive Behavior Scale. Patients report the extent to which they engage in 8 behaviors using a scale from 1 (rarely or none of the time) to 4 (most or all of the time). Scores range from 8-32 where higher scores indicate more concealment Reported values reflect the estimated slope over 6-months.
Measured by the degree of agreement (change or difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate "no pain" and high values represent "pain as bad as you can imagine".
Reported values reflect the estimated slope over 6-months.
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate "no pain" and high values represent "pain as bad as you can imagine".
Reported values reflect the estimated slope over 6-months.
Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-.38
-.70 – -.07
Arm II (Supervised Exercise Separately)
.01
-.30 – .32
Arm III (Unsupervised Exercise Separately)
-.05
-.38 – .29
6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
.27
-.04 – .58
Arm II (Supervised Exercise Separately)
-.09
-.39 – .21
Arm III (Unsupervised Exercise Separately)
.16
-.17 – .50
Fatigue IncongruencePrimary· Baseline, 3, 6 and 12 months
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's fatigue in the past 7 days using the Functional Assessment in Chronic Illness Therapy (FACIT) fatigue questionnaire. This instrument has 13 items, and possible scores from 0 to 52. Low values indicate no fatigue, while high values indicate high fatigue.
Reported values reflect the estimated slope over 6-months.
Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
1.02
-.28 – 2.32
Arm II (Supervised Exercise Separately)
-1.24
-2.50 – .03
Arm III (Unsupervised Exercise Separately)
-.41
-1.80 – .98
6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-1.20
-2.49 – .10
Arm II (Supervised Exercise Separately)
-.03
-1.30 – 1.24
Arm III (Unsupervised Exercise Separately)
-.67
-2.08 – .74
Perceived Physical Function IncongruencePrimary· Baseline, 3, 6 and 12 months
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's physical function in the past 4 weeks using the perceived physical function subscale of the SF-36 medical outcomes survey. Possible scores range from 0-100. Low scores indicate a high degree of limitation in performing physical activities, whereas high scores represent no limitations in performing physical activities due to health.
Reported values reflect the estimated slope over 6-months.
Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
.41
-.87 – 1.68
Arm II (Supervised Exercise Separately)
-.66
-1.90 – .59
Arm III (Unsupervised Exercise Separately)
-.83
-2.19 – .53
6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
1.33
.05 – 2.61
Arm II (Supervised Exercise Separately)
.62
-.64 – 1.88
Arm III (Unsupervised Exercise Separately)
1.29
-.10 – 2.69
Body Composition - Bone-free Lean MassSecondary· Baseline, 3, 6 and 12 months
Measured by bone-free lean (kg) for the whole body determined from a whole body dual energy x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
3.38
2.88 – 3.88
Arm II (Supervised Exercise Separately)
3.19
2.71 – 3.67
Arm III (Unsupervised Exercise Separately)
3.19
2.61 – 3.77
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-0.89
-1.38 – -0.39
Arm II (Supervised Exercise Separately)
-0.60
-1.06 – -0.14
Arm III (Unsupervised Exercise Separately)
-1.04
-1.59 – -0.49
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
3.20
2.73 – 3.67
Arm II (Supervised Exercise Separately)
3.32
2.86 – 3.79
Arm III (Unsupervised Exercise Separately)
3.17
2.62 – 3.72
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-1.43
-1.96 – -0.90
Arm II (Supervised Exercise Separately)
-1.03
-1.53 – -0.52
Arm III (Unsupervised Exercise Separately)
-1.05
-1.64 – -0.46
Body Composition - Fat MassSecondary· Baseline, 3, 6, and 12 months
Measured by fat mas (kg) for the whole body determined from a whole body dual x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan.
Survivor: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-3.32
-3.94 – -2.71
Arm II (Supervised Exercise Separately)
-3.50
-4.10 – -2.91
Arm III (Unsupervised Exercise Separately)
-2.77
-3.49 – -2.05
Survivor: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
1.38
0.80 – 1.96
Arm II (Supervised Exercise Separately)
1.05
0.52 – 1.59
Arm III (Unsupervised Exercise Separately)
0.53
-0.12 – 1.18
Partner: Baseline-6mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
-3.63
-4.17 – -3.09
Arm II (Supervised Exercise Separately)
-3.36
-3.90 – -2.83
Arm III (Unsupervised Exercise Separately)
-3.16
-3.79 – -2.52
Partner: 6mo-12mo
Group
Value
95% CI
Arm I (Supervised Exercise Together)
0.22
-0.56 – 0.99
Arm II (Supervised Exercise Separately)
0.87
0.14 – 1.60
Arm III (Unsupervised Exercise Separately)
0.25
-0.62 – 1.11
Adverse events — posted to ClinicalTrials.gov
Time frame: An Adverse Event survey was created by the study team to be administered monthly during the participants' year-long participation in the study..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting versus two comparator conditions where survivors and partners perform exercise routines separately in either a supervised group setting (Arm 2) or unsupervised at home (Arm 3). All three arms will train for a 6-month period and then be followed 6 months later. Data will be collected at baseline, 3, 6 and 12 months.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Anatomic Stage I Breast Cancer AJCC v8
Currently open trials in the same condition.
NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive
· Phase 2
· recruiting
NCT07158021 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
· Phase 2
· recruiting
NCT06324240 — Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
· Phase 1
· recruiting
NCT07407920 — Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
· Phase 2
· active not recruiting
NCT06876714 — ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
· Phase 3
· recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme
· Phase 1, PHASE2
· not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc
· Phase 2
· not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate
· Phase 2
· not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer
· NA
· not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03630354.